IMV Inc - ESG Rating & Company Profile powered by AI
This ESG score for IMV Inc indicates its transparency towards the UN Sustainable Development Goals. Other companies in the scoring industry group for IMV Inc are displayed. Jump to the bottom of the page for potential risks for IMV Inc based on sector, location and marketcap.
IMV Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | IMV Inc | 8.0 | High |
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does IMV Inc have an accelerator or VC vehicle to help deliver innovation?
Does IMV Inc disclose current and historical energy intensity?
Does IMV Inc report the average age of the workforce?
Does IMV Inc reference operational or capital allocation in relation to climate change?
Does IMV Inc disclose its ethnicity pay gap?
Does IMV Inc disclose cybersecurity risks?
Does IMV Inc offer flexible work?
Does IMV Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does IMV Inc disclose the number of employees in R&D functions?
Does IMV Inc conduct supply chain audits?
Does IMV Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does IMV Inc conduct 360 degree staff reviews?
Does IMV Inc disclose the individual responsible for D&I?
Does IMV Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does IMV Inc disclose current and / or historical scope 2 emissions?
Does IMV Inc disclose water use targets?
Does IMV Inc have careers partnerships with academic institutions?
Did IMV Inc have a product recall in the last two years?
Does IMV Inc disclose incidents of discrimination?
Does IMV Inc allow for Work Councils/Collective Agreements to be formed?
Has IMV Inc issued a profit warning in the past 24 months?
Does IMV Inc disclose parental leave metrics?
Does IMV Inc disclose climate scenario or pathway analysis?
Does IMV Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does IMV Inc disclose the pay ratio of women to men?
Does IMV Inc support suppliers with sustainability related research and development?
Does IMV Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does IMV Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is IMV Inc involved in embryonic stem cell research?
Does IMV Inc disclose GHG and Air Emissions intensity?
Does IMV Inc disclose its waste policy?
Does IMV Inc report according to TCFD requirements?
Does IMV Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does IMV Inc disclose energy use targets?
Does IMV Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does IMV Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for IMV Inc
These potential risks are based on the size, segment and geographies of the company.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.